Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Acute Myeloid Leukemia in the Elderly Patient: New Strategies

Acute Myeloid Leukemia in the Elderly Patient: New Strategies Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Oncology and Therapy Springer Journals

Acute Myeloid Leukemia in the Elderly Patient: New Strategies

Thomas, Xavier
Oncology and Therapy , Volume 3 (2) – Jul 4, 2015
Download PDF
11 pages

Loading next page...
 
/lp/springer-journals/acute-myeloid-leukemia-in-the-elderly-patient-new-strategies-Z33bYoX3LB
Publisher
Springer Journals
Copyright
Copyright © 2015 by The Author(s)
Subject
Medicine & Public Health; Internal Medicine
ISSN
2366-1070
eISSN
2195-6022
DOI
10.1007/s40487-015-0006-7
Publisher site
See Article on Publisher Site

Abstract

Although selected older adults with acute myeloid leukemia can benefit from intensive therapies, recent evidences support the use of lower-intensity therapies (hypomethylating agents or low-dose cytarabine) in most of these patients and emphasize the importance of tolerability and quality of life. Individualized approaches to treatment decision-making beyond consideration of chronologic age alone should therefore be considered. One promising strategy is to combine low-intensity treatments with novel agents.

Journal

Oncology and Therapy – Springer Journals

Published: Jul 4, 2015

References

  • Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry
    Juliusson, G; Antunovic, P; Derolf, A
  • Intensive chemotherapy does not benefit most older patients (age 70 years and older) with acute myeloid leukemia
    Kantarjian, H; Ravandi, F; O’Brien, S
  • Survival for older patients with acute myeloid leukemia: a population-based study
    Oran, B; Weisdorf, DJ
  • Complete remission and early death after intensive chemotherapy in patients aged 60 years or older with acute myeloid leukaemia: a Web-based application for prediction of outcomes
    Krug, U; Röllig, C; Koschmieder, A
  • A novelprognostic model in elderly patients with acute myeloid leukemia: results of 909 patients entered into the prospective AML96 trial
    Röllig, C; Thiede, C; Gramatzki, M
  • Prognostic factor analysis of the survival of elderly patients with AML in the MRC AML11 and LRF AML14 trials
    Wheatley, K; Brookes, CL; Howman, AJ
  • Questions regarding frontline therapy of acute myeloid leukemia
    Kantarjian, H; O’Brien, S
  • Outcomes and quality of care in acute myeloid leukemia over 40 years
    Alibhai, SM; Leach, M; Minden, MD; Brandwein, J
  • The hallmarks of aging
    Lopez-Otin, C; Blasco, MA; Partridge, L; Serrano, M; Kroemer, G
  • Prognostic value of immunophenotyping in elderly patients with acute myeloid leukemia: a single-institution experience
    Plesa, C; Chelghoum, Y; Plesa, A
  • Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461
    Farag, SS; Archer, KJ; Mrozek, K
  • Age-specific differences in oncogenic pathway dysregulation and anthracycline sensitivity in patients with acute myeloid leukemia
    Rao, AV; Valk, PJ; Metzeler, KH
  • Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study
    Leith, CP; Kopecky, KJ; Chen, IM
  • Blasts from elderly acute myeloid leukemia patients are characterized by low levels of culture- and drug-induced apoptosis
    Garrido, SM; Cooper, JJ; Appelbaum, FR
  • Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome
    Deschler, B; Ihorst, G; Platzbecker, U
  • Acute myeloid leukemia and myelodysplastic syndromes in older adults
    Klepin, H; Rao, A; Pardee, T
  • The relevance of geriatric assessment for elderly patients with a haematological malignancy—a systematic review
    Hamaker, ME; Prins, MC; Stauder, R
  • Age and acute myeloid leukemia
    Appelbaum, FR; Gundacker, H; Head, DR
  • Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Predictive prognostic models for outcome
    Kantarjian, H; O’Brien, S; Cortes, J
  • On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group
    Löwenberg, B; Zittoun, R; Kerkhofs, H
  • High-dose daunorubicin in older patients with acute myeloid leukemia
    Löwenberg, B; Ossenkoppele, GJ; Putten, W
  • Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
    Castaigne, S; Pautas, C; Terré, C
  • Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia
    Burnett, AK; Russell, NH; Hills, RK
  • Phase II, multicenter, randomized, open label trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus cytarabine and daunorubicin in patients with untreated AML 60–75 years of age
    Lancet, JE; Cortes, JE; Hogge, DE
  • Postremission therapy in older patients with de novo acute myeloid leukemia: a randomized trial comparing mitoxantrone and intermediate-dose cytarabine with standard-dose cytarabine
    Stone, RM; Berg, DT; George, SL
  • Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial
    Gardin, C; Turlure, P; Fagot, T
  • Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors
    Hahn, T; McCarthy, PL; Hassebroek, A
  • Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome
    McClune, BL; Weisdorf, DJ; Pedersen, TL
  • Intensive induction is effective in selected octogenarian acute myeloid leukemia patients: prognostic significance of karyotype and selected molecular markers used in the European LeukemiaNet classification
    Wetzler, M; Mrözek, K; Kohlschmidt, J
  • The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial
    Grimwade, D; Walker, H; Harrison, G
  • Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study
    Hurria, A; Togawa, K; Mohile, SG
  • Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High-Age Patients (CRASH) score
    Extermann, M; Boler, I; Reich, RR
  • A comparison of low-dose cytarabine and hydroxuyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment
    Burnett, AK; Milligan, D; Prentice, AG
  • Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse
    Kroeger, H; Jelinek, J; Estecio, MR
  • Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia
    Kantarjian, HM; Thomas, XG; Dmoszynska, A
  • Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia
    Fenaux, P; Mufti, GJ; Hellstrom-Lindberg, E
  • First clinical results of a randomized phase 2 study of SGI-110, a novel subcutaneous (SQ) hypomethylating agent (HMA), in adult patients with acute myeloid leukemia (AML)
    Kantarjian, H; Jabbour, E; Yee, K
  • The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML 14 and NCRI AML 16 pick-a-winner comparison
    Burnett, AK; Hills, RK; Hunter, AE
  • Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival
    Burnett, AK; Russell, NH; Hunter, AE
  • The addition of the farnesyl transferase inhibitor, tipifarnib, to low-dose cytarabine does not improve outcome for older patients with AML
    Burnett, AK; Russell, NH; Culligan, D
  • A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years or older with acute myeloid leukemia and high-risk myelodysplastic syndrome
    Faderl, S; Ravandi, F; Huang, X
  • A phase 2 trial of azacitidine and gemtuzumab ozogamicin therapy in older patients with acute myeloid leukemia
    Nand, S; Othus, M; Godwin, JE
  • Randomized phase 2 trial comparing low-dose cytarabine with or without volasertib in AML patients not suitable for intensive induction therapy
    Döhner, H; Lübbert, M; Fiedler, W
  • Phase I study assessing the safety and tolerability of barasertib (AZD1152) with low-dose cytosine arabinoside in elderly patients with AML
    Kantarjian, HM; Sekeres, MA; Ribrag, V
  • Stage 1 of a phase 2 study assessing the efficacy, safety, and tolerability of barasertib (AZD1152) versus low-dose cytosine arabinoside in elderly patients with acute myeloid leukemia
    Kantarjian, HM; Martinelli, G; Jabbour, EJ
  • Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Pollyea, DA; Zehnder, J; Coutre, S
  • Clinical and pharmacodynamic activity of bortezomib and decitabine in acute myeloid leukemia
    Blum, W; Schwind, S; Tarighat, SS
  • Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial
    Serve, H; Krug, U; Wagner, R
  • Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
    Ravandi, F; Alattar, ML; Grunwald, MR
  • Prognostic relevance of integrated genetic profiling in acute myeloid leukemia
    Patel, JP; Gonen, M; Figueroa, ME
  • Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia
    Schlenk, RF; Döhner, K; Krauter, J
  • Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
    Quintas-Cardama, A; Ravandi, F; Liu-Dumlao, T
  • Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associted gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study
    Becker, H; Marcicci, G; Maharry, K
  • Effects of NPM1 and FLT3 mutations on the outcomes of elderly patients with acute myeloid leukemia receiving standard chemotherapy
    Daver, N; Liu Dumlao, T; Ravandi, F
  • Clinical impact of nucleophosmin mutations and Flt3 internal tandem duplications in patients older than 60 yr with acute myeloid leukaemia
    Scholl, S; Theuer, C; Scheble, V
  • The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia
    Klepin, HD; Geiger, AM; Tooze, JA
  • Geriatric assessment in older patients with acute myeloid leukemia: a retrospective study of associated treatment and outcomes
    Sherman, AE; Motyckova, G; Fega, KR
  • Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia
    Klepin, HD; Geiger, AM; Tooze, JA
  • Impairment in functional status and survival in patients with acute myeloid leukaemia
    Wedding, U; Röhrig, B; Klippstein, A
  • A clinical trial of supervised exercise for adults inpatients with acute myeloid leukemia (AML) undergoing induction chemotherapy
    Alibhai, SM; O’Neill, S; Fisher-Schlombs, K
  • Exercise for older adult inpatients with acute myelogenous leukemia: a pilot study
    Klepin, HD; Danhauer, SC; Tooze, JA
  • Socioeconomic differences in patient survival are increasing for AML and MM in Sweden
    Kristinsson, SY; Derolf, AR; Edgren, G
  • Polypharmacy and potentially inappropriate medication use in older adults with cancer undergoing chemotherapy: effect on chemotherapy-related toxicity and hospitalization during treatment
    Maggiore, RJ; Dale, W; Gross, CP
  • Geriatric syndromes in elderly patients admitted to an oncology-acute care for elders unit
    Flood, KL; Carroll, MB; Le, CV
  • How I treat the older patient with acute myeloid leukemia
    Ossenkoppele, G; Löwenberg, B